<DOC>
	<DOCNO>NCT02685293</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , single-center , chronic-dosing ( 7 day ) , two-period , two-treatment , cross-over study evaluate treatment effect PT003 compare Placebo MDI Cardiovascular Hemodynamics follow chronic-dosing ( 7 day ) subject moderate severe COPD .</brief_summary>
	<brief_title>Study Evaluate Treatment Effect PT003 Cardiovascular Hemodynamics Subjects With Moderate Severe COPD</brief_title>
	<detailed_description />
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>At least 40 year age old 80 Visit 1 . Women nonchild bear potential , negative serum pregnancy test Screening , agree acceptable contraceptive method use consistently correctly Screening 14 day final visit Evidence lung hyperinflation Subjects establish clinical history COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) Current former smoker history least 10 packyears cigarette smoking . Pre Postbronchodilator FEV1/FVC ratio must &lt; 0.70 Postbronchodilator FEV1 must ≥30 % &lt; 65 % predict normal value , calculate use NHANES III reference equation . Significant disease condition COPD , opinion Investigator , may put patient risk Women pregnant lactate plan become pregnant course study Subjects , opinion Investigator , current diagnosis asthma active pulmonary disease Subjects hospitalize due poorly control COPD within 3 month prior Screening Subjects poorly control COPD , define acute worsen COPD require treatment oral corticosteroid antibiotic within 6 week prior Screening Screening Period Subjects clinically significant uncontrolled hypertension . Subjects symptomatic prostatic hypertrophy clinically significant adequately controlled appropriate therapy , opinion Investigator . Subjects bladder neck obstruction urinary retention clinically significant opinion Investigator . Subjects calculate creatinine clearance ≤30 mL/minute use Chronic Kidney Disease Epidemiology Collaboration . ( CKDEPI ) formula Screening repeat test prior Visit 2 . Subjects abnormal liver function test define AST , ALT , total bilirubin ≥ 1.5 time upper limit normal Screening repeat test prior Visit 2 Subjects cancer complete remission least five year . Subjects diagnosis glaucoma , opinion Investigator , adequately treat . Subjects clinically significant ECG Subjects previously enrol previous PT001 , PT003 , PT005 study conduct sponsored Pearl .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>